Cardiol Therapeutics Inc.
Clinical trials sponsored by Cardiol Therapeutics Inc., explained in plain language.
Biopharmaceutical company developing anti-inflammatory therapies for heart disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for heart lining pain: can CardiolRx keep flare-ups away? Results expected Sep 2026 (estimated) May already have reported ↗
-
Could a cannabidiol drug help heal inflamed hearts?
Disease control CompletedThis trial tests whether CardiolRx, a pharmaceutical cannabidiol, can improve heart recovery in adults with acute myocarditis (heart muscle inflammation). Participants receive either CardiolRx or a placebo for 12 weeks. The study uses heart MRI scans to measure changes in heart t…
Phase 2 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
CBD drug shows promise for stubborn heart pain
Symptom relief CompletedThis study tested a pure cannabidiol (CBD) solution called CardiolRx in 27 adults with recurrent pericarditis, a condition causing repeated inflammation and pain around the heart. Participants had not responded well to standard treatments or needed long-term steroids. The goal wa…
Phase 2 • Sponsor: Cardiol Therapeutics Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC